Xaluritamig
- Generic Name
- Xaluritamig
- Drug Type
- Biotech
- Background
Xaluritamig is a novel humanized bispecific T cell recruiting antibody cross-reactive to human and nonhuman primate STEAP1 and CD3.
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 675
- Registration Number
- NCT06691984
- Locations
- π¨π¦
Sir Mortimer B Davis - Jewish General Hospital, Montreal, Quebec, Canada
π©π°Vejle Sygehus, Vejle, Denmark
πΊπΈCity of Hope National Medical Center, Duarte, California, United States
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 30
- Registration Number
- NCT06613100
- Locations
- π©πͺ
Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany
πΊπΈUniversity of California San Francisco, San Francisco, California, United States
πΊπΈWashington University, Saint Louis, Missouri, United States
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
- Conditions
- Prostate CancerHigh-risk Biochemical RecurrenceHigh Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate CancerNon-metastatic Castration-sensitive Prostate Cancer
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 40
- Registration Number
- NCT06555796
- Locations
- πΊπΈ
Oregon Health and Science University, Portland, Oregon, United States
πΊπΈUniversity of Minnesota Medical Center Fairview, Minneapolis, Minnesota, United States
πΊπΈUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 470
- Registration Number
- NCT04221542
- Locations
- π¨π
HOCH Health Ostschweiz, Sankt Gallen, Switzerland
πΊπΈUnited States Oncology Regulatory Affairs Corporate Office, Nashville, Tennessee, United States
πΊπΈUS Oncology Research Investigational Products Center, Irving, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.